Equities

Ribomic Inc

4591:TYO

Ribomic Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)86.00
  • Today's Change3.00 / 3.61%
  • Shares traded171.60k
  • 1 Year change-50.57%
  • Beta1.1388
Data delayed at least 20 minutes, as of May 02 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

RIBOMIC Inc. is engaged in the drug discovery business based on the platform Ribomic Aptamer Refined Therapeutics System related to aptamer drug discovery technology. Its drug discovery business is divided into self discovery and co-discovery divisions. Self Drug Discovery division develops aptamer and licenses and out the results to pharmaceutical companies. The Co-Discovery division earns the research expenses paid by the alliance partner for the shared part of co-discovery business with alliance pharmaceutical companies researching aptamer pharmaceutical.

  • Revenue in JPY (TTM)62.64m
  • Net income in JPY-979.09m
  • Incorporated2003
  • Employees25.00
  • Location
    Ribomic Inc6F, Shirokanedai Usui Bldg.3-16-13, ShirokanedaiMINATO-KU 108-0071JapanJPN
  • Phone+81 334403303
  • Fax+81 334403729
  • Websitehttps://www.ribomic.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
PhoenixBio Co Ltd1.79bn113.89m1.93bn65.0024.091.0913.911.0819.8819.88401.02440.430.66251.527.1927,575,230.004.21-7.006.09-8.7767.4865.556.35-12.084.19--0.2199--60.3318.67227.16--14.18--
Modalis Therapeutics Corp0.00-2.39bn2.91bn37.00--1.91-----76.74-76.740.0041.390.00----0.00-92.78-29.19-99.33-30.02-------597.359.84--0.2301---100.00--11.50--135.50--
Atect Corp3.20bn114.29m3.00bn96.0026.191.436.520.938825.8525.85723.76474.920.57133.226.8533,330,020.002.042.032.832.7844.6847.693.573.840.7119--0.54629.40-4.032.10-6.3714.01-23.310.00
Muromachi Chemicals Inc6.12bn216.69m3.03bn205.0013.841.408.630.495153.4553.451,503.34527.871.203.833.7529,862,370.004.23--6.84--28.31--3.54--1.4526.200.4483--10.74---43.83------
Ribomic Inc62.64m-979.09m3.12bn25.00--0.8566--49.86-27.45-27.451.76100.390.0144--1.222,505,440.00-22.56-32.10-24.05-33.30-----1,563.14-1,688.5018.53--0.00---18.470.38091.88--10.04--
D.Western Therapeutics Institute Inc428.36m-812.41m3.53bn21.00--2.76--8.25-25.45-25.4513.4839.830.16070.43892.9820,398,290.00-31.09-13.06-33.75-14.3691.4494.29-193.39-72.5110.57--0.4089---4.407.90-89.07--7.08--
Kringle Pharma Inc70.58m-865.79m3.72bn13.00--1.53--52.67-158.59-158.5912.88374.930.024--0.73085,428,846.00-29.38-19.00-30.70-20.23-----1,226.76-156.5126.45-1,190.330.00---82.33---157.41------
Human Metabolome Technologies Inc1.32bn282.64m3.82bn57.0013.492.1610.462.8947.8347.83223.67299.170.630214.234.7423,186,330.0013.48--16.73--65.03--21.39--4.27151.900.1103--6.21--6.71------
FunPep Co Ltd530.00k-933.42m3.82bn15.00--1.55--7,213.76-40.11-40.110.022594.970.0002----35,333.33-34.04-27.10-35.68-28.75-----176,116.20-815.8225.95-1,765.730.00---50.33-72.8020.39---13.14--
Kubota Pharmaceutical Holdings Co Ltd39.89m-1.49bn4.00bn12.00--1.50--100.21-26.80-26.800.717547.210.01070.531714.773,323,917.00-40.06-36.51-43.86-39.4770.48---3,734.55-13,528.8710.01--0.0512--383.24--26.11--24.38--
OncoTherapy Science, Inc.901.22m-1.19bn4.00bn60.00--5.97--4.44-5.77-5.774.363.010.75895.3115.7415,020,330.00-100.44-50.21-132.58-55.41-9.03---132.35-331.973.29-258.180.00---1.6339.9756.50---57.92--
Perseus Proteomics Inc96.22m-1.12bn4.05bn24.00--2.53--42.09-95.57-95.578.18131.490.04241.8211.224,009,083.00-49.52-33.51-51.65-34.9589.0193.09-1,168.66-470.6317.58--0.00--30.96-20.89-31.38--228.18--
BrightPath Biotherapeutics Co Ltd118.00k-1.21bn4.22bn32.00--5.03--35,774.55-19.27-19.270.001911.920.00007--0.04233,687.50-71.34-42.65-89.42-44.49-433.0557.16-1,028,827.00-4,430.66---875.450.3929---65.73-56.89-0.0971---56.39--
Immuno-Biological Laboratories Co., Ltd.788.12m-192.71m4.28bn60.00--3.90--5.44-20.69-20.6984.62118.020.51440.87883.7813,135,280.00-12.58-15.11-14.85-17.6162.0656.66-24.45-50.043.490.4940.1774--22.710.9405-11.97------
Renascience Inc191.32m-331.66m4.44bn3.00--2.70--23.19-26.09-26.0915.05129.220.0851----63,772,000.00-14.74---15.49--85.75---173.36------0.1782---27.84---32.05------
MEDRx Co Ltd29.53m-932.90m4.60bn22.00--2.25--155.89-27.24-27.240.849250.170.01710.26061.221,342,455.00-54.07-58.15-58.45-62.2391.8795.70-3,158.72-1,526.1717.75--0.00---50.3528.6016.04---55.29--
Data as of May 02 2024. Currency figures normalised to Ribomic Inc's reporting currency: Japanese Yen JPY
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.